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Interleukin-17 (IL-17)-producing helper T cells (Th17
cells) play an important role in autoimmune diseases.
However, not all Th17 cells induce tissue inflamma-
tion or autoimmunity. Th17 cells require IL-23 recep-
tor (IL-23R) signaling to become pathogenic. The
transcriptional mechanisms controlling the pathoge-
nicity of Th17 cells and IL-23R expression are un-
known. Here, we demonstrate that the canonical
Notch signaling mediator RBPJ is a key driver of IL-
23R expression. In the absence of RBPJ, Th17 cells
fail to upregulate IL-23R, lack stability, and do not
induce autoimmune tissue inflammation in vivo,
whereas overexpression of IL-23R rescues this
defect and promotes pathogenicity of RBPJ-defi-
cient Th17 cells. RBPJ binds and trans-activates
the Il23r promoter and induces IL-23R expression
and represses anti-inflammatory IL-10 production
in Th17 cells. We thus find that Notch signaling influ-
ences the development of pathogenic and non-path-
ogenic Th17 cells by reciprocally regulating IL-23R
and IL-10 expression.
INTRODUCTION
Interleukin-17 (IL-17)-producing helper T cells (Th17 cells) have
been identified as a distinct subset of effector CD4+ T cells
and are considered critical drivers of autoimmune tissue inflam-
mation (Bettelli and Kuchroo, 2005; Korn et al., 2009). Differenti-
ation of naive CD4+ T cells into Th17 cells is achieved with the
cytokines transforming growth factor (TGF)-b1 and IL-6 (Bettelli
et al., 2006). This cytokine combination, however, generates
Th17 cells, which co-produce IL-10 together with IL-17 and do
not induce autoimmunity (Lee et al., 2012; McGeachy et al.,
2007) and have therefore been called non-pathogenic Th17
cells. To acquire the ability to induce autoimmunity in vivo,
IL-17-producing T cells need to either be re-stimulated with
IL-23 (McGeachy et al., 2009) or be generated with alternative
cytokine combinations triggering IL-23 receptor (IL-23R) expres-
sion and signaling, such as IL-1b, IL-6, and IL-23 (Ghoreschi392 Cell Reports 16, 392–404, July 12, 2016
This is an open access article under the CC BY-NC-ND license (http://et al., 2010) or TGF-b3 and IL-6 (Lee et al., 2012). IL-23R controls
the production of a proinflammatory transcriptional module in
Th17 cells (Lee et al., 2012), including many essential effector
cytokines (Codarri et al., 2011; El-Behi et al., 2011). IL-23R is
thus a key determinant of the pathogenicity of Th17 cells and
of autoimmunity in general (Cua et al., 2003). Understanding
the mechanism by which IL-23R regulates the functional pheno-
type of pathogenic and non-pathogenic Th17 cells and how this
balance is transcriptionally regulated is therefore critical for the
selective inhibition of pathogenic Th17 cells in human autoim-
mune diseases.
Differentiation of Th17 cells is transcriptionally controlled by
the lineage-defining transcription factor RORgt (Ivanov et al.,
2006; Xiao et al., 2014), and the transcriptional networks control-
ling Th17 cell differentiation have recently been identified in
large-scale transcriptomic analyses (Ciofani et al., 2012; Yosef
et al., 2013). Our study predicted that Notch signaling and
RBPJ, a downstream regulator of Notch signaling, were two of
the 22 major nodes that positively regulated the development
of Th17 cells (Yosef et al., 2013). This is consistent with previous
studies that demonstrated that pharmacological and antibody-
mediated inhibition of Notch ameliorated Th17-dependent auto-
immune disease models (Bassil et al., 2011; Jurynczyk et al.,
2008; Keerthivasan et al., 2011; Reynolds et al., 2011). Despite
these detailed transcriptomic data, the molecular mechanism
by which Notch regulates Th17 development has not been iden-
tified. In addition, which subtype of Th17 cells (pathogenic or
non-pathogenic) is regulated by Notch signaling has not been
addressed.
Here we demonstrate that the canonical Notch signalingmole-
cule RBPJ in Th17 cells regulates the development of pathogenic
and non-pathogenic Th17 cells. We show that RBPJ directly pro-
motes the expression of IL-23R by binding and trans-activating
the Il23r promoter and repressing anti-inflammatory IL-10 pro-
duction in Th17 cells. Consistent with this observation is that
RBPJ-deficient Th17 cells show a non-pathogenic Th17 tran-
scriptional profile, that RBPJ deficiency in Th17 cells protects
mice from the development of experimental autoimmune
encephalomyelitis (EAE), and that IL-23R overexpression res-
cues this defect. We have therefore identified a transcription
factor that controls the generation of pathogenic and non-patho-
genic Th17cells by directly driving IL-23Rexpression and repres-
sing production of the anti-inflammatory cytokine IL-10.creativecommons.org/licenses/by-nc-nd/4.0/).
RESULTS
RBPJ Is Required for the Pathogenicity of Th17 Cells
IL-23R is essential for the pathogenicity of Th17 cells, but its
transcriptional control is unknown. We previously identified
Notch1 and RBPJ, which form the Notch signaling pathway, as
predicted positive regulators of Th17 cell differentiation (Yosef
et al., 2013). However, the exact role of Notch signaling in
Th17 cells was not analyzed. In a time course expression anal-
ysis, RBPJ had high expression and was continuously upregu-
lated in Th17 cells (Figures S1A–S1C). We therefore generated
CD4CreRBPJfl/fl mice and found that RBPJ deficiency in T cells
did not affect Th17 differentiation in the presence of TGF-b1
and IL-6, a condition that induces non-pathogenic Th17 cells in-
dependent from IL-23 (Lee et al., 2012; Figure 1A). Under these
non-pathogenic conditions, CD4CreRBPJfl/fl Th17 cells instead
showed a dramatic increase in IL-10 production (Figures 1A
and 1B). When differentiated with IL-1b + IL-6 + IL-23, which
generates pathogenic Th17 cells dependent on IL-23 (Ghoreschi
et al., 2011), naive CD4CreRBPJfl/fl cells showed a significant
decrease in IL-17 expression (Figures 1C and 1D). In addition,
such pathogenic Th17 cells from CD4CreRBPJfl/fl mice began
to produce IL-10 (Figure 1D), which is normally not observed un-
der these conditions. Also, memory T cells from CD4CreRBPJfl/fl
mice that were stimulated with IL-23 showed an increase in IL-10
(Figure 1E), although IL-23 suppresses IL-10 production from
wild-type Th17 cells (Lee et al., 2012; McGeachy et al., 2009).
Lack of RBPJ thus affected the ability of Th17 cells to adequately
respond to IL-23.
To test for the in vivo relevance of these findings, we induced
the autoimmune disease model EAE in CD4CreRBPJfl/fl mice us-
ing myelin oligodendrocyte glycoprotein (MOG)35–55 peptide.
CD4CreRBPJfl/fl mice developed reduced peak severity and
had faster recovery from EAE, but disease onset was unchanged
(Figures 1F and 1G), consistent with RBPJ deficiency affecting
the generation of pathogenic Th17 cells. We isolated CNS-infil-
trating mononuclear cells from mice with EAE (Figure S1D) and
found a decrease in IL-17A-producing and IL-17A/interferon g
(IFN-g) double-producing CD4+ T cells in the CNSs of
CD4CreRBPJfl/fl mice at the peak of EAE (Figure 1H), and IL-
17A+IFN-g+ T cells are generally considered to be pathogenic
in EAE (Abromson-Leeman et al., 2009). There was no effect
on IFN-g-producing single-positive T cells and on the production
of other cytokines in the CNS at early time points (Figure S1D). At
the time of recovery, production of anti-inflammatory IL-10 by
CD4+ T cells in the CNS in CD4CreRBPJfl/fl mice was increased
(Figures 1I and 1J), whereas IL-23-dependent early generation
of Th17 cells in draining lymph nodes in CD4CreRBPJfl/fl mice
was reduced (Figure S1E). We thus hypothesized that RBPJ pro-
motes the pathogenicity of Th17 cells by altering their ability to
respond to pro-inflammatory IL-23 and/or by repressing the pro-
duction of anti-inflammatory IL-10.
RBPJ is known to have a role in the differentiation of other
T helper cells (Amsen et al., 2009), and, accordingly, we
observed an increased differentiation of Th1 cells (Figure S1F)
and decreased generation of induced regulatory T cells (iTregs)
(Figure S1G) in CD4CreRBPJfl/fl mice. To circumvent these non-
Th17-derived effects, we crossed RBPJfl/fl mice to IL17ACremice to delete RBPJ only in IL-17A-producing cells. The differen-
tiation of Th1 (Figure S2A) and iTreg (Figure S2B) cells was un-
changed in IL17ACreRBPJfl/fl cells, supporting that the loss of
RBPJ is indeed restricted to IL-17-producing T cells in this
mouse line.
When differentiating IL17ACreRBPJfl/fl cells under non-patho-
genic Th17 conditions (TGF-b1 + IL-6), RBPJwas indeed deleted
(Figure S2C), and we observed an increase in IL-10 production
but little effect on IL-17 production (Figures 2A and 2B). In
contrast, under pathogenic differentiation conditions (IL-1b,
IL-6, and IL-23), which require the effect of IL-23R signaling,
IL-17A production was significantly reduced in IL17ACreRBPJfl/fl
cells (Figures 2C and 2D), whereas IL-10 protein was not detect-
able (data not shown). After immunization with MOG35–55,
IL17ACreRBPJfl/fl mice developed less severe EAE than wild-
type controls (Figures 2E and 2F), with a significant reduction
in peak EAE severity but no change in disease onset. At the
peak of EAE, fewer CNS-infiltrating CD4+ cells produced IL-17
and IL-17/IFN-g concurrently (Figure 2G) in IL17ACreRBPJfl/fl
mice, and there was a trend toward more IL-10+ CD4+ T cells
at recovery that did not reach statistical significance (Figure 2H).
Production of other cytokines was unchanged (Figure S2D).
Moreover, the IL-23-dependent generation of Th17 cells was
affected in the periphery (Figure S2E), and IL17ACreRBPJfl/fl cells
producedmore IL-10 at recovery (Figure 2I).We next co-cultured
IL17ACreRBPJfl/fl cells with congenically marked wild-type cells
and found a marked reduction in pathogenic Th17 cell differen-
tiation only in CD45.2+ IL17ACreRBPJfl/fl cells in comparison
with the cocultured CD45.1+ wild-type cells, arguing for a cell-
intrinsic effect of RBPJ in Th17 cells (Figure S2F). Thus, Th17
cell-restricted RBPJ deficiency also impairs their response to
pro-inflammatory IL-23 and their pathogenicity.
IL-17A is also expressed by gd T cells and innate lymphoid
cells. To exclude the contribution of such cell types and to
address the role of RBPJ specifically in pathogenic Th17 cells
in vivo, we crossed CD4CreRBPJfl/fl mice to 2D2 mice, which ex-
press a MOG35–55-specific T cell receptor (TCR) transgene (Bet-
telli et al., 2003). Th17cellsdifferentiated in vitrounderpathogenic
Th17 conditions from CD4CreRBPJfl/fl 2D2 mice and were unable
to induceEAEuponadoptive transfer, in contrast towild-type2D2
Th17 cells (Figure 2J), although their IL-17 production before
transfer was unchanged (Figure S2G). Our data obtained with
this targeted deletion of RBPJ thus indicate that RBPJ is required
specifically for the differentiation of pathogenic Th17 cells
generated with IL-23 and that loss of RBPJ results in an increase
in anti-inflammatory IL-10 and loss of pathogenicity in vivo. RBPJ
deficiency thus causes the generation of non-pathogenic Th17
cells even under pathogenic Th17 differentiation conditions.
Notch signaling controls various aspects of CD4+ T cell func-
tion, including chemokine receptor expression (Reynolds et al.,
2011) and viability of memory T cells (Helbig et al., 2012; Mae-
kawa et al., 2015). We did not find evidence for an altered
expression of Ccr6 (Figure S3A) or an altered survival of RBPJ-
deficient Th17 cells in vitro (Figure S3C) or in vivo (Figures S3D
and S3E), arguing for a specific effect of RBPJ on the pathoge-
nicity of Th17 cells under IL-23-dependent Th17 differentiation
conditions. We next investigated the mechanism of how RBPJ
enhanced pathogenicity of Th17 cells.Cell Reports 16, 392–404, July 12, 2016 393
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Figure 1. RBPJ in T Cells Maintains the Pathogenicity of Th17 Cells
(A) Naive CD4+CD62LhighCD44lowCD25 T cells were sorted from RBPJflox/flox and CD4CreRBPJflox/flox mice, differentiated with TGF-b1 and IL-6, and analyzed by
intracellular cytokine staining after 4 days.
(B) Cytokine ELISA of cultures described in (A). ns, not significant.
(C) Naive T cells were differentiated with IL-1b, IL-6, and IL-23.
(D) Cytokine ELISA of cultures described in (C). nd, not detected.
(E) CD4+CD62LlowCD44highCD25 memory T cells were sorted from RBPJflox/flox and CD4CreRBPJflox/flox mice, cultured with IL-23 for 5 days, and stained for
intracellular cytokines.
One representative of five independent experiments is shown in (A)–(E).
(F) Active EAE was induced in RBPJflox/flox (n = 26) and CD4CreRBPJflox/flox (n = 26) mice by subcutaneous immunization with 100 mg of MOG35–55 peptide in
complete Freund’s adjuvant together with intraperitoneal injection of pertussis toxin (200 ng) on days 0 and 2.
(G) Regression analysis of the clinical scores observed between days 12 and 28.
(H) CNS-infiltrating mononuclear cells were extracted and stained for intracellular cytokines on day 15 after immunization (d15). The percentage of CNS-infil-
trating, cytokine-producing CD4+ cells was calculated.
(I) The cytokine production by CNS-infiltrating CD4+ cells was assessed on d28, and the proportion of IL-10-producing CD4+ T cells was calculated.
(J) CNS-infiltrating CD4+ T cells were sorted from RBPJflox/flox (n = 3) and CD4CreRBPJflox/flox (n = 3) mice, and relative Il10 expression was measured by qPCR
using GAPDH as a housekeeping gene.
Results are summed from three independent experiments in (F–I), with three individual mice analyzed per group in (H) and (I). *p < 0.05, **p < 0.01. See also
Figure S1.RBPJ Controls the Expression of IL-23R in Th17 Cells
We performed a multiplex gene expression analysis using nano-
string technology, applying a codeset of 200 predefined Th17-
related transcripts (Yosef et al., 2013) and comparing the results
with a previously defined pathogenic/non-pathogenic Th17 gene
signature (Lee et al., 2012). Non-pathogenic Th17 cells (TGF-b1+
IL-6) differentiated from IL17ACreRBPJfl/fl mice showed a
reduced expression of Il23r and increased expression of Il10 (Fig-
ure 3A) that is part of a regulatorymodule in non-pathogenic Th17394 Cell Reports 16, 392–404, July 12, 2016cells. Conversely, the expression of Il23r, Il22, and Casp1 was
reduced in pathogenic Th17 cells (IL-1b + IL-6 + IL-23) differenti-
ated from IL17ACreRBPJfl/fl mice (Figure 3B). These transcripts
were previously identified as part of a pro-inflammatory module
in pathogenic Th17 cells (Lee et al., 2012). In addition, Il17a,
which is the effector cytokine of pathogenic Th17 cells, was
downregulated under both conditions in IL17ACreRBPJfl/fl cells.
RBPJ thus partly controls the expression of both pathogenic
and non-pathogenic signature genes in Th17 cells.
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Figure 2. RBPJ Is Required in Th17 Cells to Maintain Their Pathogenicity
(A) Naive CD4+CD62LhighCD44lowCD25 T cells were sorted fromRBPJflox/flox and IL17ACreRBPJflox/flox mice, differentiated with TGF-b1 and IL-6, and stained for
intracellular cytokines after 4 days.
(B) Cytokine ELISA of cultures described in (A).
(C) Naive T cells were differentiated in vitro with IL-1b, IL-6, and IL-23 and analyzed as in (A).
(D) Cytokine ELISA of cultures described in (C).
One representative of five independent experiments is shown in (A)–(D).
(E) RBPJflox/flox (n = 43) and IL17ACreRBPJflox/flox (n = 28) mice were immunized subcutaneously with MOG35–55 peptide emulsified in complete Freund’s adjuvant
with intraperitoneal injections of pertussis toxin.
(F) Regression analysis of the clinical scores observed between days 12 and 28.
The data in (E) and (F) are summed from five independent experiments.
(G) CNS-infiltrating cells were extracted and analyzed by intracellular cytokine staining on day 15 after immunization.
(H) CNS-infiltrating lymphocytes were stained for intracellular cytokines on d28, and the percentage of IL-10+ CD4+ cells was calculated.
(I) Draining lymph node cells of mice on d15 were restimulated in vitro with 10 mg/ml MOG35–55 peptide and IL-23 for 5 days. Cytokine concentrations were
measured by ELISA.
(J) Naive CD4+CD62LhighCD44lowCD25 T cells were sorted from wild-type 2D2 and CD4CreRBPJfl/fl 2D2 mice and differentiated in vitro with TGF-b1, IL-6, and
IL-23. Sfter 7 days of culture, 5 3 106 cytokine-producing T cells were intravenously injected into C57BL/6 wild-type recipients.
The data in (G–I) are summed from three independent experiments with 3–5 mice/group. *p < 0.05, **p < 0.01. See also Figure S2.IL-23 promotes the pathogenicity and stability of Th17 cells.
We next addressed whether RBPJ affects the stability of the
Th17 cell lineage by crossing IL17ACreRBPJfl/fl mice with
R26RFP mice, generating IL-17A fate reporter mice as described
previously (Hirota et al., 2011; Figure S3F). Th17 cells differenti-
ated in vitro from IL17ACreRBPJfl/flR26RFP mice had unchanged
red fluorescent protein (RFP) expression (Figure 3C), indicatingan unchanged initial commitment to the Th17 lineage. Instead,
we observed a reduced production of IL-17 by CD4+RFP+ (i.e.,
lineage-committed Th17 cells) generated under pathogenic dif-
ferentiation conditions (IL-1b + IL-6 + IL-23) but not under non-
pathogenic conditions (TGF-b1 + IL-6) from IL17ACreRBPJflllf
R26RFP mice (Figure S3G). This indicates that RBPJ deficiency
affects Th17 stability only under IL-23-dependent differentiationCell Reports 16, 392–404, July 12, 2016 395
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Figure 3. RBPJ-Deficient Th17 Cells Show Non-pathogenic Gene Expression and Are Unstable In Vitro Because of a Lack of IL-23R
Expression
(A) Naive CD4+CD62LhighCD44lowCD25 T cells were sorted from IL17ACreRBPJflox/wt and IL17ACreRBPJflox/flox mice and differentiated with TGF-b1 and IL-6.
Expression of a pre-defined set of Th17-relevant genes was quantified using Nanostring nCounter after 4 days of culture.
(B)An identical experiment as in (A) using naive CD4+ cells differentiated with IL-1b, IL-6, and IL-23.
Average values from three independent experiments with technical duplicates per sample are depicted in (A and B) as fold change of IL17ACreRBPJflox/flox versus
IL17ACreRBPJflox/wt cells. Please note that Il10 is upregulated 1.47-fold (data not shown) but does not reach the defined cutoff for minimum read counts;
i.e., transcript abundance. The cutoff for differentially regulated genes wasR1.25-fold regulation.
(C) Naive T cells from IL17ACreRBPJflox/wtR26RFP and IL17ACreRBPJflox/floxR26RFP mice were differentiated in vitro with TGF-b1 and IL-6 or IL-1b, IL-6, and IL-23
for 4 days, and the proportion of CD4+RFP+ cells was assessed by flow cytometry.
(D) CD4+RFP+ cells were sorted from cultures differentiated with TGF-b1 and IL-6 described in (C) and analyzed for gene expression using Nanostring nCounter.
Expression is depicted as fold-change of IL17ACreRBPJflox/floxR26RFP versus IL17ACreRBPJflox/wtR26RFP cells. The cutoff for differentially regulated genes
wasR1.25-fold, and changes were averaged from three independent experiments.
(E) Naive T cells were differentiated with TGF-b1 and IL-6 from IL17ACreRBPJflox/wtR26RFP and IL17ACreRBPJflox/floxR26RFP mice as in (D). Live CD4+RFP+ cells
were sorted from the cultures and restimulated in vitro for 3 days with IL-23 only. Cytokine production was assessed before (d4) and after (d7) restimulation after
gating on live RFP+ cells.
(F) IL17ACreRBPJflox/wtR26RFP (Rfl/wt) and IL17ACreRBPJflox/floxR26RFP (Rfl/fl) mice were immunized with MOG35–55, and, at the peak of EAE, draining lymph nodes
cells were cultured in the presence of 1 mg/mlMOGand IL-23 for 5 days. Intracellular cytokine production was assessed after gating on CD4+ (top) and CD4+RFP+
(bottom) cells. Data are summarized from four independent mice in three independent experiments.
(G) Il23r promoter-driven GFP fluorescence was quantified in naive T cells differentiated for 4 days without cytokines from IL17ACreRBPJflox/wtIL23RGFP/wt mice
(red histogram) or with IL-1b, IL-6, and IL-23 from IL17ACreRBPJflox/wtIL23RGFP/wt mice (blue histogram) and IL17ACreRBPJflox/floxIL23RGFP/wt mice (orange
histogram).
(H) Naive CD4+ T cells were sorted fromRBPJflox/flox and CD4CreRBPJflox/flox mice and differentiated with IL-1b, IL-6, and IL-23 for 4 days. IL-23Rwas detected by
cell surface staining for IL-23R.
The data in (C), (E), (G), and (H) are representative of three independent experiments. *p < 0.05. See also Figure S3.
396 Cell Reports 16, 392–404, July 12, 2016
BA
Lu
ci
fe
ra
se
 a
ct
iv
ity
Lu
ci
fe
ra
se
 a
ct
iv
ity
 
in6 in3 p1 p2 p3 p4 p5
0.00
0.05
0.10
0.15
0.20
In
pu
t (
%
)
in6 in3 p1p2 p3p4 p5
2kb
Il23r
- - - -
1
2
3
0
2
4
6
8
10
cMaf cMaf caRBPJ caRBPJ
pGL4-IL23R pGL4 pGL4-IL23R pGL4
C
Lu
ci
fe
ra
se
 a
ct
iv
ity
caRBPJ
-
0
1
2
3
pTA-IL23R
Lu
ci
fe
ra
se
 a
ct
iv
ity
caRBPJ
-0
1
2
3
pTA-IL23RΔp2
Lu
ci
fe
ra
se
 a
ct
iv
ity
cMaf
-0
4
2
6
8
pTA-IL23RΔp2
E
caRBPJ RV
caRBPJ RV
empty RV
empty RV
IL23Rwt/wt
Th0
C
el
ls
 (r
el
at
iv
e)
IL-23R-GFP
F
CD4CreRORγtfl/fl
RORγtfl/fl
IL-23R-PE
CD4
10.5% 16.3%
4.34% 8.14%
G
Lu
ci
fe
ra
se
 a
ct
iv
ity
caRBPJ caRBPJ
RORγt
RORγt
+
- - -
pGL4-IL23R
0
1
2
3
4
5
D
Lu
ci
fe
ra
se
 a
ct
iv
ity
caRBPJ -
pGL4-Il23R pGL4-Il23R pGL4-Il23R pGL4-Il23R
-
RBPJ -
cMaf ---
0
5
10
15
*
*
RBPJflox/flox
CD4CreRBPJflox/flox
0
2
4
6
Lu
ci
fe
ra
se
 a
ct
iv
ity
 
cMaf
pTA-IL23R
-
Figure 4. RBPJ Binds and trans-Activates the Il23r Promoter and Induces IL-23R Expression in Cooperation with RORgt
(A) Naive CD4+ T cells were sorted from RBPJflox/flox and CD4CreRBPJflox/flox mice and differentiated with TGF-b1 and IL-6 for 4 days, followed by IL-23 for 3 days.
Cross-linked protein-DNA complexes were immunoprecipitated using an anti-RBPJ antibody. DNA was purified and used for qPCR with primers spanning parts
of the Il23r promoter predicted to contain RBPJ binding sites, indicated as horizontal bars in the schematic of the Il23r locus. in, intron; p, promoter. DNA binding
was calculated as percentage of input DNA. One representative of three independent experiments with three replicate samples per immunoprecipitation (IP) is
shown.
(B) Il23r promoter activity wasmeasured in HEK293T cells transfectedwith a luciferase vector driven by 2.7 kb of the IL23R promoter (pGL4-IL23R) and increasing
amounts of constructs encoding c-Maf and (ca)RBPJ (RBPJ-VP16).
(C) IL23r promoter activity was measured after transfection with a luciferase vector driven by 1.5 kb of the IL23R promoter (pTA-IL23R) and constructs encoding
c-Maf and caRBPJ (RBPJ-VP16). Luciferase activity induced by c-Maf andRBPJ-VP16wasmeasured using a pTA-IL23R promoter construct withmutated RBPJ
binding site p2 (pTA-IL23RDp2).
(D) pGL4-IL23R luciferase activity was measured after transfection with combinations of RBPJ, caRBPJ, and c-Maf constructs.
(legend continued on next page)
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conditions. We also tested how efficiently the RBPJfl/fl allele was
deleted by the IL17ACre allele and found a marked reduction but
no absence of RBPJ in CD4+RFP+ cells (Figure S3H). Even the
reduction of RBPJ expression in the IL17ACreRBPJflox mouse
line is thus sufficient to impair an adequate response to IL-23
in Th17 cells.
We next sorted CD4+RFP+ cells, which constitute lineage-
committed Th17 cells, following in vitro differentiation with
TGF-b1 + IL-6 and subjected them to nanostring analysis. Of
note, expression of Il23r and Il21 was lower in RBPJ-deficient
CD4+RFP+ cells compared with RBPJ-competent cells (Fig-
ure 3D). When we cultured these sorted CD4+RFP+ cells in the
presence of IL-23 to test their stability, IL17ACreRBPJflllfR26RFP
cells lost IL-17 and gained IL-10 production to a greater extent
than controls (Figure 3E). We also used the IL17ACre
RBPJflllfR26RFP mouse to address the lineage ontogeny of the
CD4+IL-10+ population we had observed in draining lymph no-
des in the absence of RBPJ (Figure 2I). We found that a greater
proportion of RFP+ cells was IL-10+ in IL17ACreRBPJflllfR26RFP
mice (Figure 3F), indicating that the increased IL-10+ cells in
the absence of RBPJ derive from Th17 cells. Together, these
data indicate that RBPJ-deficient T cells are unaffected in their
initial commitment to the Th17 lineage but lose stability and
expression of members of the pathogenic transcriptional mod-
ule, including IL-23R, while gaining expression of members of
the regulatory module. We thus speculated that RBPJ helps to
maintain the stability of the Th17 lineage by directly regulating
the expression of IL-23R.
To address this, we examined the protein expression of IL-23R
in pathogenic Th17 cells, which are known to express high levels
of IL-23R (Lee et al., 2012). We crossed IL17ACreRBPJfl/fl mice
with IL23RGFP reporter mice (Awasthi et al., 2009) and found
that pathogenic Th17 cells from IL17ACreRBPJfl/flIL23RGFP
mice showed reducedGFP expression compared with heterozy-
gous IL17ACreRBPJfl/wtIL23RGFP controls (Figure 3G). IL-23R
surface levels were also reduced in pathogenic Th17 cells from
CD4CreRBPJfl/fl mice stained with an anti-IL-23R antibody (Fig-
ure 3H), confirming that RBPJ is, in fact, required to induce
IL-23R protein expression in Th17 cells. A reduction in IL-23R
expression was also observed in RBPJ-deficient non-patho-
genic Th17 cells, albeit at lower levels because of the low
expression of IL-23R under these conditions (data not shown).
Furthermore, activation of the Notch pathway by overexpression
of the intracellular domain of Notch receptors 1–3 (NICD) also
induced surface expression of IL-23R in Th17 cells (Figure S4A).
RBPJ and the Notch signaling pathway thus promote expression
of the IL-23R, and RBPJ is consequently required for the stability
and pathogenicity of Th17 cells.The data in (B–D) are representative of five independent experiments.
(E) Naive T cells were sorted from IL23RGFP/wt reporter mice and transduced with
encoding caRBPJ (MSCV-RBPJ-VP16-Thy1.1) and cultured without cytokines. G
of culture.
(F) Naive T cells were sorted from Rorgtflox/flox and CD4CreRorgtflox/flox mice and t
IL-23R was analyzed after 4 days in culture after gating on live CD4+Thy1.1+ cell
(G) IL23r promoter activity was measured in HEK293T cells transfected with the
or both.
Luciferase activities were calculated as fold empty vector in (B–D) and (G). One r
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We next addressed how RBPJ controls the expression of the IL-
23R on a transcriptional level. We identified canonical RBPJ
binding sites (Wang et al., 2011) in the proximal and distal pro-
moter region (Figure 4A) and in both enhancer regions in intron
3 and intron 6 of the Il23r gene (Figure 4A), where Th17-related
transcription factors such as RORgt bind (Xiao et al., 2014). To
experimentally test for binding of RBPJ, we performed chromatin
immunoprecipitation (ChIP) PCR of the predicted RBPJ binding
sites. Il23r promoter regions—preferentially a region 1,100 bp
upstreamof the transcriptional start site termed p2—showed en-
riched binding (Figure 4A), indicating that RBPJ indeed binds the
Il23r promoter. Of note, the site with most enrichment (p2) is
distinct from sites bound by other Th17 cell-related transcription
factors (Ciofani et al., 2012; Xiao et al., 2014; Yosef et al., 2013).
Using a previously described IL23R promoter luciferase
construct spanning 1.2 kb of the Il23r promoter (pTA-Il23r),
constitutively active (ca) RBPJ (RBPJ-VP16) trans-activated
the Il23r promoter (Figure 4B). c-Maf, which is known to activate
Il23r expression (Sato et al., 2011), was used as a positive con-
trol. Mutating site p2 in this construct abrogated its activation
by caRBPJ but not by c-Maf (Figure 4C). This indicates that
RBPJ directly controls transcription from the Il23r promoter
dominantly through the p2 binding site, which is distinct and in-
dependent from other Th17 cell-related transcription factors. We
next tested whether non-modified RBPJ exerted repressive ef-
fects on the Il23r promoter. Non-modified RBPJ had no effect
on c-Maf-induced Il23r promoter activation, whereas caRBPJ
had additive effects together with c-Maf on the Il23r luciferase
construct (Figure 4D). Thus, the Notch pathway drives IL-23R
expression through direct transcriptional control.
We next addressed whether RBPJ acted independently or in
cooperation with the Th17 cell lineage-defining transcription fac-
tor RORgt, which was previously shown to bind the Il23r pro-
moter at moderate levels (Ciofani et al., 2012; Xiao et al.,
2014). Retroviral overexpression of caRBPJ induced IL23RGFP
reporter expression even in Th0 cells, which do not express
RORgt (Figure 4E). Also, caRBPJ induced surface expression
of IL-23R in the absence of RORgt in CD4CreRORgtflox/flox cells
cultured in the presence of IL-1b + IL-6 + IL-23 (Figure 4F). In
accordance, both caRBPJ and RORgt individually activated
the Il23r promoter luciferase construct and, when combined, ex-
hibited an additive effect in inducing IL-23R expression (Fig-
ure 4G). RBPJ did not interact directly with RORgt on the protein
level (Figure S4B). Taken together, our data indicate that the
Th17 transcriptional program is not required for RBPJ to pro-
mote the expression of IL-23R but that RBPJ and RORgt mayeither an empty retrovirus (RV) (murine stem cell virus [MSCV]-Thy1.1) or a RV
FP expression was detected after gating on live CD4+Thy1.1+ cells after 4 days
ransduced with either an empty RV or caRBPJ RV. Cell surface expression of
s.
pGL4-IL23R vector and increasing amounts of caRBPJ and Rorgt constructs
epresentative of three independent experiments is shown in (E)–(G). *p < 0.05.
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Figure 5. RBPJ Is Required to Promote IL-
23R Expression Rather Than IL-17 in Th17
Cells
(A) Naive T cells from IL17ACreRBPJflox/wt and
IL17ACreRBPJflox/flox mice were transduced with
either an empty RV or with an RV encoding mouse
IL-23R and stained for intracellular cytokines after
differentiation with IL-1b, IL-6, and IL-23 for
4 days. Gating was on live CD4+GFP+ cells.
(B) The percentage of IL-17+ cells was calculated,
defining empty RV in IL17ACreRBPJflox/wt cells as
100% in each experiment. Significance was
calculated using Student’s t test for paired
samples.
(C) Naive T cells were sorted from IL17ACre
RBPJflox/wtIL23RGFP/GFP and IL17ACreRBPJflox/flox
IL23RGFP/GFP mice and differentiated with IL-1b,
IL-6, and IL-23. Intracellular cytokine staining was
performed after 4 days.
(D) Cytokine ELISA of cell culture supernatants
described in (C).
One representative of three independent experi-
ments is shown in (C) and (D).
(E) Naive T cells were sorted from wild-type 2D2
and CD4CreRBPJfl/fl 2D2 mice and, during Th17
differentiation, were transduced with either an
empty or IL-23R-encoding RV. After 7 days of
culture, 6 3 106 cytokine-producing T cells were
intravenously injected into C57BL/6 wild-type re-
cipients. The clinical score was assessed daily.
(F) Naive T cells were sorted from wild-type 2D2
and CD4CreRBPJfl/fl 2D2 mice and, during Th17
differentiation in vitro, transduced with a lentivirus
(LV) encoding both Cas9 and an IL-10-targeting
CRISPR guide RNA or Cas9 only (empty). After
7 days of culture, 8 3 106 cytokine-producing
T cells were intravenously injected into C57BL/6
wild-type recipients.
The data in (A) are representative of and in (B) are
summarized from four independent experiments.
*p < 0.05.work in a combinatorial manner to induce maximum expression
of IL-23R but do not form a protein-protein complex.
The Dominant Function of RBPJ in Th17 Cells Is to
Maintain IL-23R Expression
Our data indicate that RBPJ controls the generation and stability
of pathogenic Th17 cells by directly driving IL-23R transcription.
Previous studies, however, had reported that Notch controls
transcription of IL-17A and RORgt itself, although not testing
for changes in IL-23R expression (Keerthivasan et al., 2011; Mu-
kherjee et al., 2009), and we replicated these findings (Figures
S5A–S5C). We thus wanted to address whether RBPJ primarily
controls Th17 cell differentiation through regulating IL-17A
expression or through regulating IL-23R expression.
To this end, we retrovirally overexpressed IL-23R in IL17ACre
RBPJfl/fl Th17 cells during differentiation under pathogenic
Th17 conditions (IL-1b + IL-6 + IL-23), where IL-23R is required
to stabilize IL-17 production and is maximally expressed in
wild-type cells. Overexpression of IL-23R partly rescued the
loss of IL-17A production in IL17ACreRBPJfl/fl cells (Figures 5A
and 5B), although the effect was small. To further dissectwhether RBPJ mainly controls expression of IL-17 or IL-23R,
we generated IL-23R/RBPJ double-deficient mice by crossing
IL17ACreRBPJfl/fl mice with IL23RGFP/GFP mice that lack func-
tional IL-23R at homozygosity (Awasthi et al., 2009). Pathogenic
Th17 cells (IL-1b + IL-6 + IL-23) differentiated from IL-23R/RBPJ
double-deficient IL17ACreRBPJfl/flIL23RGFP/GFP mice showed no
significant change in IL-17 production compared with IL-23R
deficient/RBPJ-competent IL17ACreRBPJfl/wtIL23RGFP/GFP mice
(Figures 5C and 5D). This was in contrast to the reduced differen-
tiation of pathogenic Th17 cells we had observed in IL17ACre
RBPJfl/fl mice (Figures 2C and 2D) and indicates that RBPJ
deficiency impairs Th17 cell differentiation only in the presence
of IL-23R. Similar effects were observed in CD4CreRBPJfl/fl
IL23RGFP/GFP mice (data not shown).
To address the importance of RBPJ in driving IL-23R expres-
sion versus IL-17 expression in vivo, we retrovirally overex-
pressed IL-23R in pathogenic 2D2 (expressing a MOG35–55-spe-
cific TCR) Th17 cells before transferring them into wild-type
hosts. We found that overexpression of IL-23R partially rescued
the protection from EAE conferred by RBPJ deficiency (Fig-
ure 5E). Conversely, knockout of IL-10 in 2D2 Th17 cells usingCell Reports 16, 392–404, July 12, 2016 399
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Figure 6. RBPJ Represses c-Maf-Induced
IL-10 Production in Th17 Cells
(A) Sorted naive RBPJflox/flox and CD4Cre
RBPJflox/flox CD4+ T cells were transduced with
either empty MSCV-GFP or MSCV-cMaf-GFP RV,
cultured with TGF-b1 and IL-6 for 4 days, and
analyzed by intracellular cytokine staining.
(B) Cell culture supernatants from cultures
described in (A) were analyzed by ELISA.
(C) Naive CD4+ T cells were sorted from
RBPJflox/flox and CD4CreRBPJflox/flox mice and
differentiated in vitro with TGF-b1 and IL-6 for
4 days, followed by IL-23 for 3 days. Cross-linked
protein-DNA complexes were immunoprecipi-
tated with an anti-RBPJ antibody. DNA was puri-
fied and used for qPCR spanning predicted RBPJ
binding sites in the IL-10 promoter. DNA binding
was calculated as percentage of input DNA. Pre-
dicted RBPJ-binding sites are indicated as p1–p8,
and previously identified MARE sites (Apetoh
et al., 2010) are indicated as M1–M4. One repre-
sentative of four independent experiments is
shown, with three replicate IPs per sample.
(D) Il10 promoter activity was measured in
HEK293T cells transfected with the pGL4-IL10-
1.5kb luciferase vector and constructs encoding
c-Maf and RBPJ. Luciferase activities were
calculated as fold change compared with the
empty vector.
One representative of three independent experi-
ments is shown in (A), (B), and (D). *p < 0.05.a clustered regularly interspaced short palindromic repeats/
CRISPR associated protein 9 (CRISPR/Cas9) lentiviral system
did not rescue the protection from EAE conferred by RBPJ defi-
ciency (Figure 5F), and neutralization of IL-10 did not revert
protection from actively induced EAE in CD4CreRBPJfl/fl mice
(Figure S5D). Together, these data indicate that driving IL-23R
expression, not driving IL-17 or repressing IL-10, is the dominant
function of RBPJ in Th17 cells in vivo.
Of note, RBPJ-deficient IL17ACreRBPJfl/flIL23RGFP/GFP patho-
genic (IL-1b + IL-6 + IL-23) Th17 cells also produced higher
amounts of IL-10 detected by ELISA, although not by intracel-
lular cytokine staining, than RBPJ-competent IL17ACreRBPJfl/wt
IL23RGFP/GFP Th17 cells (Figure 5D). Thus, RBPJ deficiency
enhances production of the non-pathogenic cytokine IL-10
even in the absence of IL-23R. This indicated that RBPJ may
also serve as a repressor of IL-10 production in Th17 cells
in vitro independently from its effect on IL-23R expression and
although this is not its dominant function in vivo (Figures 5E
and 5F).
RBPJ Serves as a Repressor of c-Maf-induced IL-10
Production in Th17 Cells
The transcription factor c-Maf is a known inducer of IL-10 in type
1 regulatory (Tr1) cells induced by IL-27 (Apetoh et al., 2010) and
in Th17 cells (Bauquet et al., 2009; Xu et al., 2009), and we thus
speculated that RBPJ may act as a repressor of the regulatory
module, including IL-10 controlled by c-Maf in Th17 cells. We
overexpressed c-Maf in Th17 cells generated in the presence
of TGF-b1 + IL-6 and found that, in CD4CreRBPJfl/fl cells, c-Maf400 Cell Reports 16, 392–404, July 12, 2016overexpression induced more IL-10 than in wild-type cells (Fig-
ures 6A and 6B). We conclude that RBPJ may serve as a tran-
scriptional repressor of c-Maf-induced IL-10 expression in
Th17 cells. The IL-10 genomic locus contains multiple predicted
RBPJ binding sites, and ChIP-PCR confirmed binding of RBPJ
to the IL-10 locus in Th17 cells (Figure 6C). Of note, two previ-
ously identified c-Maf response elements (MAREs) in the Il10
promoter (Apetoh et al., 2010) were located within a 150-bp
range of predicted RBPJ binding sites (Figure 6C). We did not
observe protein-protein interaction between RBPJ and c-Maf
(Figure S6). Using a luciferase assay, we observed that non-
modified RBPJ inhibited c-Maf-induced activation of the IL-10
promoter (Figure 6D), indicating that RBPJ can indeed repress
IL-10 production induced by c-Maf. In conclusion, we identify
RBPJ as an essential transcriptional regulator controlling the
generation of pathogenic and non-pathogenic Th17 cells by
promoting the expression of IL-23R and repressing the produc-
tion of IL-10. However, the effects of RBPJ on IL-23R are
dominant in promoting the pathogenic phenotype of Th17 cells
in vivo.
DISCUSSION
Our previously generated transcriptional network of Th17 cells
implicated RBPJ, the canonical Notch signaling molecule, as a
positive regulator of Th17 differentiation (Yosef et al., 2013).
Although the previous study had relied on analysis and pertur-
bation on the mRNA level, here we examined RBPJ in Th17 cells
with technically more stringent approaches by testing for the
in vitro differentiation and the in vivo function of Th17 cells in the
absence of RBPJ and identifying the mechanisms by which
RBPJ controls Th17 cell differentiation. Using different genetic
approaches, we observed that RBPJ deficiency does not affect
the early stage of Th17 cell differentiation but, rather, affects the
stabilization stage when Th17 cells are rendered pathogenic
through the effects of IL-23. We further demonstrate that
RBPJ is required to maintain a pathogenic state of Th17 cells
by driving expression of IL-23R and by repressing production
of the anti-inflammatory cytokine IL-10. RBPJ thus serves a
highly specific purpose in Th17 cells: to promote the pathoge-
nicity of Th17 cells by promoting the expression of members
of the pro-inflammatory module and repressing expression of
the regulatory module. Therefore, this observation expands
the array of functions of the Notch signaling pathway in the dif-
ferentiation of various T cell subsets (reviewed in Amsen et al.
(2009).
Consistent with our observations, pharmacological inhibition
of Notch cleavage or Notch ligand binding was previously
shown to ameliorate EAE (Bassil et al., 2011; Jurynczyk et al.,
2008; Keerthivasan et al., 2011; Maekawa et al., 2015; Rey-
nolds et al., 2011), but the mechanisms were not elucidated.
Here we did not rely on pharmacological inhibitors but, rather,
used genetic approaches to ablate the canonical Notch sig-
naling molecule RBPJ in a cell-type-specific manner in Th17
cells. Driving Cre expression from the endogenous Il17a pro-
moter or from an Il17f bacterial artificial chromosome/clone
(BAC) transgenic line (Croxford et al., 2009; Hirota et al.,
2011) allows deletion of RBPJ in all IL-17-expressing cells.
RBPJ deletion by Il17a promoter-driven Cre expression was
well detectable but did not reach 100% deletion, indicating
that RBPJ mRNA may persist after recombination of the Rbpj
genomic locus, providing a potential explanation for the
more subtle in vitro phenotype in IL17ACreRBPJfl/fl than in
CD4CreRBPJfl/fl cells. Therefore, combining our data derived
from the CD4Cre and IL17ACre lines and using the 2D2 adoptive
transfer model, in which RBPJ-deletion was specifically tar-
geted to CNS-specific pathogenic Th17 cells, and by overex-
pressing IL-23R, we demonstrate that RBPJ is required for
the pathogenicity of Th17 cells by directly controlling IL-23R
expression. IL-23 did not induce the expression of RBPJ, indi-
cating that RBPJ is an important upstream controller of IL-23R
expression but does not form a positive feedforward loop with
IL-23R signaling.
Canonical Notch signaling serves a multitude of functions in
T cells. It controls thymic development of T cells (Tanigaki and
Honjo, 2007), the differentiation of several T helper cell lineages
(Amsen et al., 2009; Bailis et al., 2013), the longevity of helper
cells in vitro (Helbig et al., 2012), the expression of chemokine re-
ceptors in vitro (Reynolds et al., 2011), and the survival of mem-
ory T cells in a re-stimulation paradigm in vivo (Maekawa et al.,
2015). However, by using Th17 cell-specific deletion of RBPJ,
we did not find evidence for survival-related effects in our exper-
imental setting (Figures S5A–S5E), and, by overexpressing
IL-23R (Figure 5), we demonstrate that RBPJ regulates Th17
pathogenicity specifically by controlling IL-23R expression. By
generating RBPJ/IL-23R double-deficient mice and by overex-
pressing IL-23R in Th17 cells transferred in vivo, we also demon-strate that the dominant function of RBPJ in Th17 cells in vivo is
to promote the expression of IL-23R and the pathogenic func-
tional state of Th17 cells.
Th17 cells do not all induce autoimmune disease. It is
becoming increasingly clear that Th17 cells mediate tissue ho-
meostasis at mucosal surfaces. In fact, IL-17 production by
T cells may serve a protective function in the gut without
inducing tissue inflammation (O’Connor et al., 2009), and gut-
resident Th17 cells partly resemble non-pathogenic Th17 cells
that co-produce IL-17 and IL-10 (Esplugues et al., 2011; Ga-
gliani et al., 2015). These different functional states of Th17
cells may have evolutionarily arisen to defend against specific
pathogens, as shown in humans (Zielinski et al., 2012). Identi-
fying the factors controlling the balance between such patho-
genic and non-pathogenic Th17 cells may provide the key to
understanding how to inhibit pathogenic Th17 cells that induce
tissue inflammation and autoimmune diseases but spare those
that maintain gut barrier functions and promote tissue homeo-
stasis. Our data indicate that the Notch signaling pathway may
be one of the key checkpoints in determining the balance be-
tween the pathogenic and non-pathogenic states of Th17 cells.
The biological importance is further strengthened by genetic
linkage of the RBPJ genomic locus with rheumatoid arthritis
(Stahl et al., 2010), in which Th17 cells are important (Miossec
and Kolls, 2012).
In the canonical Notch signaling pathway, RBPJ is bound to
DNA and acts as a transcriptional repressor in the absence of
NICD (Amsen et al., 2009). Only after ligand binding will NICD
trans-locate to the nucleus and convert RBPJ to a transcrip-
tional co-activator (Amsen et al., 2009). RBPJ can thus exert
dual functions as either a transcriptional repressor or inducer
depending on the nuclear availability of NICD and, thus, on
the activity of the Notch pathway. This dual function of RBPJ
may account for the induction of IL-10 by NICD in Th1 cells
(Kassner et al., 2010; Rutz et al., 2008) but inhibition of IL-10
by RBPJ, which we describe here. In fact, overexpression of
NICD also induces IL-10 in Th17 cells (data not shown) in
accordance with the dual role of RBPJ as transcriptional acti-
vator or repressor. We describe here that the Il10 and Il23r
loci respond differently to RBPJ-mediated repression in the
absence of Notch pathway activation. RBPJ does not alter
cMaf-induced transcription of the Il23r locus but inhibits
cMaf-induced transcription of the Il10 locus (Figure 6). The
activity of the Notch signaling pathway may thus serve as a
transcriptional switch to determine how c-Maf and potentially
other transcription factors control the transcription of IL-10
and IL-23R expression in Th17 cells.
We describe here a dual function of RBPJ in Th17 cells as
both promoting pathogenicity by inducing IL-23R expression
and inhibiting the production of anti-inflammatory IL-10. We
therefore identify RBPJ as a transcriptional switch in Th17 cells
and provide a mechanistic explanation of how RBPJ can pro-
mote the generation of pathogenic Th17 cells and inhibit the
generation of non-pathogenic Th17 cells. Our identification of
RBPJ as a regulator that can differentially affect pathogenic
and non-pathogenic Th17 cells will offer targets to inhibit path-
ogenic Th17 cells but spare beneficial tissue-protective Th17
cells.Cell Reports 16, 392–404, July 12, 2016 401
EXPERIMENTAL PROCEDURES
Animals and EAE
CD4Cre mice were from Taconic. B6.SJL-PtprcaPepcb/BoyJ mice (named
CD45.1) and B6;129S6-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J mice (Madisen
et al., 2010) (named R26RFP), were from The Jackson Laboratory. IL17ACre (Hir-
ota et al., 2011), RBPJflox (Tanigaki et al., 2002), IL23RGFP (Awasthi et al., 2009),
and 2D2 (Bettelli et al., 2003) mice were described previously. All experiments
were carried out in accordance with guidelines prescribed by the Institutional
Animal Care and Use Committee (IACUC) at Harvard Medical School. Age-
and sex-matched mice (7–9 weeks old) were immunized for EAE as described
previously (Xiao et al., 2014). IL-10 neutralization in vivo was performed with
500 mg of low endotoxin azide-free rat immunoglobulin G1 (IgG1) or anti-IL-
10 antibody (clone JES5-16E3, BioLegend) intraperitoneally on days 0, 2,
and 7 as described previously (McGeachy et al., 2007). Adoptive transfer of
EAE using Th17 differentiated 2D2 cells was performed as described previ-
ously (Ja¨ger et al., 2009). For transduction before adoptive transfer, 2D2 cells
were spin-infected (6003 g for 45 min at 25C) with retroviral supernatants on
day 1 after plating with Polybrene (8 mg/ml) or with lentiviral supernatants. Cells
were not sorted or selected for transduction before transfer.
CD4+ T Cell Differentiation and Retroviral Transduction
CD4+CD44lowCD62LhighCD25 naive CD4+ T cells were purified by flow
cytometry following magnetic activated cell sorting (MACS) bead isolation of
CD4+ cells. Naive T cells were activated with plate-bound anti-CD3 (2 mg/ml,
145-2C11) and anti-CD28 (2 mg/ml, PV-1) antibody in 96-well or 24-well plates.
In vitro T cell differentiation was performed for 96 hr. For non-pathogenic Th17
cell differentiation, cultures were supplemented with IL-6 (20 ng/ml) and
TGF-b1 (2 ng/ml). For pathogenic Th17 cell differentiation, cultures were sup-
plemented with IL-1b (20 ng/ml), IL-6 (20 ng/ml), and IL-23 (10 ng/ml). Retro-
virus-containing supernatants were produced by transiently transfecting
HEK293T producer cells with retroviral packaging constructs (PCL-Eco,
gag/pol) together with retroviral expression plasmids using Fugene HD
(Roche). Culture supernatants were harvested after 72 hr, supplemented
with Polybrene (8 mg/ml), and added to sorted naive T cells previously stimu-
lated for 24 hr (1 3 105 cells/well, 96-well plate, plate-bound anti-CD3/CD28,
both 2 mg/ml, and indicated cytokines). Cultures were centrifuged at 600 3 g
for 45 min at 25C. After an additional 72 hr of culturing, intracellular cytokine
staining was performed. Gating was on CD4+7AADThy1.1+ cells. The
CRISPR/Cas9 was described previously (Parnas et al., 2015). Cas9 was driven
by amodified embryonal fyn-associated substrate (EF-S) promoter, and single
guide RNA (sgRNA) was driven by a mammalian U6 promoter. Packaging was
with a vesicular stomatitis virus G protein (VSV-G) envelope.
Generation of Constructs and Luciferase Assays
The pTA-IL23R plasmid was described previously (Sato et al., 2011). The pTA-
IL23RDp2 plasmid was generated by PCR site-directed mutagenesis modifying
the GTGGGAA sequence at 1,151 bp from the Il23r transcriptional start site
(TSS) to GTAAAAA. The pGL4-IL23R construct was generated by PCR, ampli-
fying a 2.7-kb part of the Il23r promoter (2.714 to 0 bp from TSS) from a
mouse BAC clone (RPCI-23-34P19, Bacterial artificial chromosome [BAC]/
P1-derived artificial chromosome [PAC] Children’s Hospital Oakland Research
Institute [CHORI] repository) and cloning the product into the pGL4.10 vector
(Promega) using NheI/EcoRV sites. The coding part of all constructs was veri-
fied by sequencing. Luciferase assays were performed in HEK293T cells using
the Dual-Luciferase reporter assay system (Promega). The firefly luciferase
activity was normalized to Renilla luciferase activity and is expressed as rela-
tive values compared with the empty vector control.
Statistics
The clinical score of EAE was analyzed by Fisher’s exact test. All other
results were analyzed by Student’s t test. p < 0.05 was considered significant
(*p < 0.05; **p < 0.01). Statistical analysis was performed using GraphPad
Prism 5.0.
For a detailed description of all experimental procedures, see the Supple-
mental Experimental Procedures.402 Cell Reports 16, 392–404, July 12, 2016SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2016.05.088.
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